Literature DB >> 25750489

Simplified Warfarin Dose-response Pharmacodynamic Models.

Seongho Kim1, Adam E Gaweda2, Dongfeng Wu3, Lang Li4, Shesh N Rai3, Michael E Brier5.   

Abstract

Warfarin is a frequently used oral anticoagulant for long-term prevention and treatment of thromboembolic events. Due to its narrow therapeutic range and large inter-individual dose-response variability, it is highly desirable to personalize warfarin dosing. However, the complexity of the conventional kinetic-pharmacodynamic (K-PD) models hampers the development of the personalized dose management. To avert this challenge, we propose simplified PD models for warfarin dose-response relationship, which is motivated by ideas from control theory. The simplified models were further applied to longitudinal data of 37 patients undergoing anticoagulation treatment using the standard two-stage approach and then compared with the conventional K-PD models. Data analysis shows that all models have a similar predictive ability, but the simplified models are most parsimonious.

Entities:  

Keywords:  dose-response model; kinetic-pharmacodynamics; mixed-effects model; standard two-stage approach

Year:  2015        PMID: 25750489      PMCID: PMC4349334          DOI: 10.4015/S1016237215500015

Source DB:  PubMed          Journal:  Biomed Eng (Singapore)        ISSN: 1016-2372


  10 in total

1.  A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

Authors:  A-K Hamberg; M Wadelius; J D Lindh; M L Dahl; R Padrini; P Deloukas; A Rane; E N Jonsson
Journal:  Clin Pharmacol Ther       Date:  2010-04-21       Impact factor: 6.875

2.  Individualization of pharmacological anemia management using reinforcement learning.

Authors:  Adam E Gaweda; Mehmet K Muezzinoglu; George R Aronoff; Alfred A Jacobs; Jacek M Zurada; Michael E Brier
Journal:  Neural Netw       Date:  2005 Jun-Jul

3.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

4.  A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

Authors:  A-K Hamberg; M-L Dahl; M Barban; M G Scordo; M Wadelius; V Pengo; R Padrini; E N Jonsson
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

Review 5.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin; J T Brandt
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

6.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

7.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

8.  A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models.

Authors:  Seongho Kim; Stephen D Hall; Lang Li
Journal:  J Biopharm Stat       Date:  2009-07       Impact factor: 1.051

Review 9.  Control-relevant modeling in drug delivery.

Authors:  R S Parker; F J Doyle
Journal:  Adv Drug Deliv Rev       Date:  2001-06-11       Impact factor: 15.470

10.  Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Amanda S Grove; Stephanie Barton; Zachery P Nicholas; Samera F S Kahn; Heidi T May; Kent M Samuelson; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2007-11-07       Impact factor: 29.690

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.